The challenging situation of ER+ and human epidermal growth factor receptor 2-positive (HER2+) MBC is also shortly reviewed to underline the complexity of the clinical scenario in the heterogeneous subgroups of ER+ breast cancer patients and the increasing need for personalised medicine. This evidence concerns the gene ESR1 and breast cancer.